Title
Category
Credits
Event date
Cost
Management of Acute Myeloid Leukemia in 2020: A Paradigm Shift for Older Adults? - SPOC
  • Research to Practice
  • 1.00 Participation
$0.00
Dr. Joshua Zeidner will discuss updates in the diagnostic testing and prognostic subclassifications of AML which drive therapeutic decisions. This presentation will highlight perceived paradigm shifts for AML and older adults.
Prostate Cancer Management in North Carolina: Updates for 2020 - SPOC
  • Research to Practice
  • 1.00 Participation
$0.00
Young Whang, MD, from the UNC Lineberger Genitourinary Oncology group will describe relevant updates in systemic therapy for prostate cancers for health care providers throughout the state of North Carolina. Additional topical management considerations or recommendations for this patient population may also be presented.
Head and Neck Cancer Management in North Carolina: Updates for 2020 - SPOC
  • Research to Practice
  • 1.00 Participation
$0.00
Dr. Siddharth Sheth from the UNC Lineberger Head and Neck Oncology group will describe relevant updates in systemic therapy for head and neck cancers for health care providers throughout the state of North Carolina. Additional topical management considerations or recommendations for this patient population may also be presented.
Multiple Myeloma in North Carolina: Updates - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
The management of multiple myeloma is dynamic with a constantly changing landscape. Samuel M. Rubinstein, MD, MSCI, will cover recently published manuscripts and conference presentations that present practice changing data in the management of multiple myeloma.
Update in Bladder Cancer - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 ODS
  • 1.25 NCPD/CNE
  • 1.00 Participation
$0.00
Matthew I. Milowsky, MD, FASCO, presents on "Update in Bladder Cancer"
Antibody-Drug Conjugates in Oncology: From Bench to Bedside - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 ODS
  • 1.25 NCPD/CNE
  • 1.00 Participation
$0.00
Kevin Chen, PharmD, MS, BCOP, CPP, presents on "Antibody-Drug Conjugates in Oncology: From Bench to Bedside."
Obesity and Cancer Prevention: The Efficacy and Timing of Bariatric Surgery - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.50 ASRT
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Join Maggie M. Hodges, MD, MPH, for a surgeon's perspective on the role of cancer risk reduction through bariatric surgery, while also exploring the optimal timing of bariatric surgery in patients with a personal history of cancer.
Radiation Oncology Management of Lung Cancer in NC: Update on Small-Cell Lung Cancer - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Ashley Weiner, MD, PhD, presents on the role of radiotherapy for small-cell lung cancer. She provides overview of radiation oncology, and a walk through a patient's pathway from initial consultation with a radiation oncologist to treatment and follow-up. Finally, she reviews the indications for, logistics of, and side effects of radiation for the treatment of small cell lung cancer (limited and extensive stage).
Immune (check point) Related Adverse Events - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Frances Collichio, MD, reviews the common and uncommon side effects of immune check point inhibitors. She also discusses the relatively new concept of delayed immune related events.
Primary Brain Tumors: Diagnosis and Management Strategies - SPOC
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ODS
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Dominique Higgins, MD, PhD, provides an overview of diagnostic criteria for primary CNS brain tumors, and the current approved and investigational treatments that are available and on the horizon.

Pages